Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: AccuMed/Olympus

This article was originally published in The Gray Sheet

Executive Summary

AccuMed/Olympus: AccuMed ships the first 25 AcCell 2000 and 2001 automated cytopathology systems to Olympus, fulfilling initial shipment requirements under a recent distribution agreement. The agreement gives Olympus exclusive rights in the Western Hemisphere to distribute AccuMed's AcCell workstations, which are used in screening Pap smear and other cell samples. The deal also includes rights to the yet-to-be-approved AccuMap system, which employs software to "map and automatically focus the cell specimen prior to human screening," AccuMed says. AccuMed plans to begin training Olympus' technical and quality personnel during the week of July 8. In cooperation with Olympus, AccuMed can continue to promote the system in the Americas...

You may also be interested in...

QUOTED. 27 November 2020. Agam Sharda.

The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Swissmedic Clears Up Confusion Over Validity Of GMP Certificates

Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts